Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · LeMaitre Vascular (LMAT)

LeMaitre Q4 sales rise 14% to $55.7 million, EPS $0.49; 2025 guidance issued

Positive Impact 3 of 5 earnings Written later

LeMaitre Vascular reported preliminary fourth-quarter 2024 results, with net sales of $55.7 million, up 14% from a year earlier, and diluted EPS of $0.49 versus $0.38. The company also gave 2025 guidance of $235.4 million to $242.8 million in sales and $2.15 to $2.32 in EPS, and raised its quarterly dividend 25% to $0.20 per share. Sales and earnings growth, plus the dividend increase and a share repurchase authorization of up to $75.0 million, are the main items for shareholders.

Key points

  • Q4 2024 net income was $11.2 million, versus $8.5 million in Q4 2023; operating income was $12.9 million, up 26%.
  • Gross margin was 69.3%, up from 68.1% in Q4 2023.
  • 2025 full-year sales guidance is $235.4 million to $242.8 million, compared with 2024 sales of $219.9 million.
  • The quarterly dividend rises to $0.20 per share, payable March 27, 2025; the board authorized up to $75.0 million in buybacks through February 17, 2026.

The filing

CompanyLeMaitre Vascular (LMAT)
Form8-K, current report
Filed with the SECFeb 27, 2025, 4:40 PM ET
Accession number0001437749-25-005495

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:55 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 27, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.